Biotech Layoffs Hit Evotec, Vistagen; Immutep Shares Plunge
Evotec, Vistagen lay off staff; Immutep shares collapse on study failure https://t.co/OikmCdJ6sg $EVO $VTGN $IMMP - 81% $RARE $ATRA
Key Challenges and Strategies for Conducting Ex‑US Trials
"Ex-US Clinical Trials: Tribulations, Preparations, and Expectations" - new From The Trenches blog from @ArthurTzianabos, CEO of Lifordi and seasoned drug developer, on the considerations for ex-US clinical trials... https://t.co/IZ6RUVKrZj
Correct Lung Target, Yet IMMP’s
Lung (not head & neck) was the right choice for $IMMP to pursue in phase 3, but it still failed. Stock -89%. Sory via @APEXONCO -> https://t.co/Y1ilGP5Aqq
CBD and CBG Reverse Fatty Liver in Mice
I teach medical students that fatty liver disease (MASLD) affects 1 in 3 adults and has limited approved drug treatments. That may be changing. Hebrew University researchers found CBD and CBG -- two non-psychoactive cannabis compounds -- reversed fatty liver in mice...
Market‑First Synthetic Biology: Validate Demand Before Scaling Science
When Erum Khan asked me why 80% of biotech companies fail at execution, I replied: "The majority of synthetic biology founders have become enamored with the tool, the technology that they developed and then they went out there with that hammer...
FDA Approves GSK Arexvy for At‑risk Adults 18‑49
#GSK Arexvy RSV Vaccine approved by US FDA with a wider indication for Adults aged 18 to 49 who are at increased risk of Lower Respiratory Tract Disease caused by RSV.
Jefferies Paints WVE Data as Win‑win‑win; Bear Sees Combo Role
Doing some reading ahead of the next wave of $WVE INHBE "body composition" 🙄 data, smirking at the Jefferies analyst set up, which basically frames 6-month data as a win-win-win for the stock price. His "bear case" "Bear case would still...
Eli Lilly Surges to #1 Pharma Sales in 2025
Another testimony of Eli Lilly’s increasing dominance in the BioTech and Pharma sector - compared to other Big Pharma companies - such as $PFE $JNJ $NVS $NVO $BMY $ABBV $MRK $SNY and others, can be seen in this excellent @NatRevDrugDisc...
New Cancer Interception Strategy Regresses Pancreatic Precancers
🆕 @ScienceMagazine An exciting new approach vs pancreatic cancer: "cancer interception" Considered ubiquitous, the pancreas in healthy adults has hundreds of PanINs of microscopic premalignant cancer that can be regressed in the experimental model https://t.co/erVtthSMjS https://t.co/2xHIYdIPrx
Low‑dose Rapamycin Eases Fatigue and PEM in ME/CFS
Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a complex, multisystem disorder characterized by profound fatigue… 👉 “Low-dose rapamycin effectively reduced PEM and other key...
FDA Reform Essential for Real Longevity Breakthroughs
I love the longevity proponents on X But we WON'T get true longevity therapeutics if we don't reform the FDA or find a way around them. The FDA is still a quagmire of regulatory rot that has to be reformed to get...
Lilly Warns GLP‑1 Knockoffs Are Dangerous, Intensifies Compounder Battle
Lilly warns GLP-1 knockoffs may be ‘dangerous,’ escalating war with compounders https://t.co/XOKLqIzAES @ByJonGardner $LLY $NVO #obesity
Why Peptide Enthusiasts Fear Tested Vaccines
Can someone explain to me why many of the same folks who love experimenting with peptides (i.e. little to no rigorous safety data) are terrified of vaccines and other drugs that have testing... How does someone square that circle?
RFK Jr Promotes Unproven Peptides, BPC‑157 Lacks Solid Data
RFK Jr is trying to get 14 peptides, without data on safety or efficacy, licensed and approved by FDA. His favorite is BPC-157. "Only three small human studies of BPC-157 exist, for instance, the largest of which is a telephone...
Pierre Fabre, ATRA to Meet FDA on Ebvallo CRL Soon
Pierre Fabre and $ATRA said FDA meeting to discuss the Ebvallo CRL has been scheduled. (Likely occuring within the next month.)
FDA Cracks Down on Misleading GLP‑1 Telehealth Marketing
The FDA is targeting telehealth marketing of GLP-1 drugs. Who’s prescribing them? Medical groups face ‘tricky’ questions when partners make misleading claims via @KatieMPalmer https://t.co/pf4Fwa7W7r
Join Final FDA Advisory Committee on Flu Shot Access
If you are curious about seeing what may be the last competent FDA advisory committee left standing in action as they contribute to determining access to flu shots next fall, join me, @jessicamalaty, & @SaveAmericaMvm at 12:30 pm ET on...
New Tissue Models Accelerate Liver Disease Drug Development
New tissue models could help researchers develop drugs for liver disease by Anne Trafton @MIT Learn more: https://t.co/hkeRZ0W47B #HealthTech #EmergingTech #TechForGood #Innovation https://t.co/LNvft8iX9M
Phase 2 Trial Compares Dara‑Bor
EAA241 - Ph 2 RCT Dara-Bor-Dex vs Cy-Bor-Dex in the treatment of Newly Diagnosed Multiple Myeloma with Light Chain Cast Nephropathy (LCCN) [Study activated 8/11/25] @keruakous https://t.co/1NgvVZ3fTA #NCT07085728 #mmsm @eaonc https://t.co/IvK3UNeem9
Phase 3
#EAOnc EQUATE EAA181 Effective Quadruplet Utilization After Tx Evaluation: Ph3 RCT NDMM Not Intended for Early ASCT [Activated: 10/27/20] PI= @myelomaMD https://t.co/qD26HMx3J8 #NCT04566328 #mmMRD #mmsm @eaonc @mweissmdphd @VincentRK @LynneWagnerPhD Wei Snyder Kostakoglu @mtmdphd https://t.co/FLK0sJ0N1w
Daratumumab Boosts Revlimid Efficacy in Smoldering Myeloma
#EAonc EAA173 - Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM) - PI: @nsc_natalie https://t.co/VtBMJUjI5X Activated: Apr 30, 2019 #mmsm @eaonc #NCT03937635 @VincentRK @mweissmdphd https://t.co/ikQKjHjscU
Phase 3 Trial Tests
.@SWOG S2213 Ph3 RCT Dara-VC Induction Followed by ASCT or Dara-VCD Consolidation & Daratumumab Maintenance in Pts w/ Newly Diagnosed AL Amyloidosis [Activated: 12/1/23] https://t.co/OizUfJCc2c #mmsm #bmtsm https://t.co/FoT3i0xGcL
Mapping Genomic Alterations in Multiple Myeloma Precursors
Genomic landscape of multiple myeloma and its precursor conditions [May 21, 2025] Jean-Baptiste Alberge et al. @IrenemGhobrial @NatureGenet https://t.co/DDWGRrpI4Y #mmsm #PrecisionMedicine #cagenome https://t.co/LY1MzFXSBN
Multiple Myeloma Evades GPRC5D T‑Cell Engagers via Multim
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myeloma [Jan 15, 2026] @hollyleeYJ et al. @NBahlis @NatureMedicine https://t.co/mz393mPMAq #mmsm #PrecisionMedicine #tcellrx THREAD: https://t.co/lNX9b7LsnR HT @AuclairDan https://t.co/2qih7LwP1c
Sen. Markey Admits He Doesn
Sen. Markey (D-Mass.) tells me outside the Capitol he doesn’t know who Vinay Prasad is and would need to be briefed by staff to respond to questions on the FDA
Regulation Will Push Peptide Market to Clean Providers
Consider this arc: peptides were around in niche communities, GLPs from Pharma then exploded, people realized they could take less or source them elsewhere, regulation enters & now gray & black market are going bye-bye & companies like HIMs &...
Net Pricing Could Cut Patients' Drug Costs by 40%
If big pharma sold to big 3 distributors at net prices rather than list prices, patients would save on average 40pct on their specialty and brand medications. This isn't hard. @BernieSanders @HawleyMO @SenTedCruz @SenateGOP @SenWarren @AOC https://t.co/COdRaMJPgq
Emerging KRAS Combo Therapies Show Promising Progress
The KRAS niche has been a deluge of new selective and pan/multi inhibitors. Now there are combos to watch out for – we may be making progress. Here are insights on 7 of them: https://t.co/F9HmM8A4ud https://t.co/IqWw6n2m3k
GLP‑1 Drug Linked to Longer Survival in Brain Metastases
Another potential GLP-1 drug benefit seen in people with diabetes and brain metastases for improved survival; a retrospective study that needs further assessment but intriguing https://t.co/nZm3xEYQMH https://t.co/V76S7o1MJb
DNA Repair Gene Changes Shape NSCLC Immune Landscape
DNA damage repair gene alterations influence the tumor immune microenvironment in advanced non-small cell lung cancer [Feb 14, 2025] @KamyaSankar et al. @ReckampK Lung Cancer https://t.co/mXZ80zYke3 #lcsm #ImmunoOnc #PrecisionMedicine @TempusAI https://t.co/UJwZnw4qnc
New Immune Profile Score Predicts ICI Outcomes
Development & Validation of The Immune Profile Score (IPS), a Novel Multiomic Algorithmic Assay For Stratifying Outcomes in a Real-World Cohort of Pts w/ Adv Solid Cancer Tx'd w/ Immune Checkpoint Inhibitors [May 30, 2025] Zander etal @jitcancer https://t.co/rN5KIoVgPy #ImmunoOnc
BRAF Class II/III Mutations Represent Unmet Clinical Need
Real-world clinical genomic analysis of Pts w/ BRAF mutated cancers identifies BRAF class II & III as a population of unmet medical need [3/7/22] Severson et al #ESMO2240P @TempusLabs https://t.co/s5PEBEczlv @Annals_OncologyDOI: https://t.co/c3wxWyUuX0 #PrecisionMedicine #caxtx
Targeting Mitochondrial Redox Balance to Create Geroprotectors
Mitochondria and Aging: Redox Balance Modulation as a New Approach to the Development of Innovative Geroprotectors (Fundamental and Applied Aspects) https://t.co/TcG9GjMVg7 @IJMS_MDPI https://t.co/gxCC9SsO7z
Vima Raises $100M to Develop Oral Movement Disorder Drug
With $100M, Vima pursues an oral drug for movement disorders https://t.co/gLrhlYDMSy by @gwendolynawu #biotech #startups
Average-Onset CRC Shows Higher BRAF Mutation Rates
Genomic Landscapes of Early-Onset vs Average-Onset Colorectal Cancer Populations [Feb 28, 2025] Storandt et al. @Cancers_MDPI https://t.co/as7Jolal12 #crcsm #PrecisionMedicine most significant difference b/w eoCRC & aoCRC was higher rates of BRAF mutation among Pts w/ aoCRC https://t.co/7qB4b3A1WK
Biotech Winter: Funding Freeze, IPO Surge, Path to Thaw
Biotech Science at Less Than Zero | Ep. 955 https://t.co/4DXKsaKXdO [00:49] Biotech capital winter deep dive [01:17] Scientific leaps vs frozen markets [02:31] The 2020–2021 biotech bubble [03:42] Crossover funds fuel IPO surge [04:56] Interest rates freeze biotech funding [07:58] Negative enterprise value phenomenon [10:37] Why Big Pharma...
New Nonprofit Secures $500M to Upgrade Science for AI
New nonprofit launches with at least $500 million to modernize scientific process for AI era https://t.co/yuypno6rVY via @ADeAngelis_bio
No RCTs for BPC‑157: Patent Dead, Profit Absent
Correct. There will likely be no RCTs on BPC. Unless a new variant can perform better and be patented and Rx’d… and THATs happening.
Senescent Cells Fuel Atherosclerosis; Senolytics Offer Hope
The Role of Cellular Senescence and SASP in the Pathogenesis of Atherosclerosis and the Therapeutic Potential of Senolytic Strategies in Cardiovascular Diseases "Cellular senescence and SASP drive chronic inflammation and vascular dysfunction central to atherosclerosis pathogenesis, with senescent endothelial cells, VSMCs,...
Melatonin Shields Mitochondria, Offering Neurodegenerative Therapy
Melatonin as a Guardian of Mitochondria: Mechanisms and Therapeutic Potential in Neurodegenerative Diseases https://t.co/kp4LZEbZzN https://t.co/boWzW7fcjM
Weight‑loss Meds Cut Alcohol Use in Half of Users
Study shows nearly half of weight loss participants reduced alcohol use after starting anti-obesity medication (GLP-1 agonists, metformin, naltrexone). https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2827069 https://www.gatlan.com/ @GatlanHealth
Leucovorin Approved for Limited Autism Subgroup, Not Mass Treatment
Last fall the administration was talking about leucovorin as a potential treatment for large numbers of people with #autism. Today's approval suggests the evidence supports its use in a much smaller group of people, @rosebroderick_ reports. https://t.co/NlJR8KlaqP
BioNTech Founders Leave to Launch New mRNA Venture
BioNTech founders to step down and helm new mRNA startup https://t.co/yjvsVRQH2D by @Lilah_Alvarado $BNTX - 20%
Xenon Scores Epilepsy Win; FDA Revives Duchenne Cell Therapy Review
Xenon hits a ‘home run’ in epilepsy; FDA restarts review of Duchenne cell therapy https://t.co/l40xYeW2Xh $XENE $CAPR + 15% $REGN $PFE $ABBV $GSK #biotech
BBIO, ALNY Surge on Pfizer Tafamidis Patent Win
$BBIO $ALNY moving higher on apparently good news re: Pfizer's tafamidis patent defense. If you have access to Umer Raffat's research, he has all the details.
Psilocybin Plus Therapy Boosts Quit Rates Sixfold
🚨 @NPR spotlights our new JAMA Network Open study: One psilocybin dose + therapy gives 6X better odds of quitting smoking vs. nicotine patch + therapy. Game-changer for tobacco smoking addiction?
Blood Test Predicts Alzheimer's up to 25 Years Early
Predicting Alzheimer's disease up to 25 years in advance of any symptoms with the p-tau217 biomarker blood test, among 2,766 women mean age 70 https://t.co/aOActAUN27 https://t.co/Bxl2YZxnlf
DNA Repair Mutations Predict Response to Chemo‑Immunotherapy in Pancreatic Cancer
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma https://t.co/v39bOreJwu
FDA Adds Six Former Members, Total Nine Voters
Correction: I took down a post about Thursday's #VRBPAC meeting because it contained an error. #FDA has named 6 temporary voting members (not 2), which will bring the number for the meeting to 9. The temps are all former members....
FDA Accepts CAPR's Deramiocel Resubmission, Decision Aug 22
$CAPR resubmission of the deramiocel application accepted by the FDA. New decision date: Aug. 22. https://t.co/mWSyyXg8di